Spoken Alpha
NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals develops novel therapeutics for central nervous system disorders including suicidal depression, PTSD, chronic pain, and schizophrenia. The company's lead candidates—NRX-100 and KETAFREE (preservative-free ketamine formulations) and NRX-101 (an oral combination of D-cycloserine and lurasidone)—are in FDA review for approval.
NRX Pharmaceuticals, Inc has a $714.6M market cap.
Most recent reported earnings: Q2 FY2021 (Sep 29, 2021).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-05-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NRXPW.
$ curl https://api.spokenalpha.com/v1/companies/NRXPWFAQ
Spoken Alpha indexes NRXPW's earnings call transcripts at https://spokenalpha.com/companies/NRXPW. Each call links to attributed speakers and parsed analyst Q&A. NRX Pharmaceuticals, Inc.'s own investor relations page is at https://ir.nrxpharma.com/.
NRX Pharmaceuticals, Inc. (NRXPW) held its most recent earnings call on 2026-05-18, covering fiscal Q1 2026.
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2021 | 2021-09-29 | $-0.40 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2021 | 2021-06-29 | $-6.51 | $0.00 | — | $-113.1K | — | — | EODHD |
| Q4 FY2020 | 2021-03-30 | $-2.26 | $0.00 | — | — | — | — | EODHD |
| Q2 FY2020 | 2020-09-29 | $-0.15 | $0.00 | — | $25.0K | — | — | EODHD |
| Q1 FY2020 | 2020-06-29 | $0.00 | $0.00 | — | $113.1K | — | — | EODHD |
| Q4 FY2019 | 2020-03-30 | $-0.15 | $0.00 | — | $172.3K | — | — | EODHD |
Source: EODHD. NRXPW reported actuals as published; sparse fields render as —.